Table 2—

Results of overall meta-analysis for the comparison of acarbose and miglitol versus placebo and sulfonylurea

OutcomePlacebo-controlled studies
Sulfonylurea-controlled studies
Acarbose
Miglitol
Acarbose
Miglitol
Comp, part*Effect size95% CIComp, part*Effect size95% CIComp, part*Effect size95% CIComp, part*Effect size95% CI
GHb (%)28, 2,831−0.77−0.90-−0.647, 1,088−0.68−0.93-−0.448, 5960.38–0.02-0.771, 900.40−0.16-0.96
Fasting blood glucose (mmol/l)28, 2,838−1.09−1.36-−0.832, 398−0.52−0.88-−0.168, 5960.690.16-1.231, 900.27−0.74-1.28
1-h postload blood glucose (mmol/l)22, 2,238−2.32−2.73-−1.922, 398−2.70−5.54-0.148, 591−0.10−0.43-0.221, 88−0.60−3.43-2.23
Fasting insulin (pmol/l)15, 1,264−0.5−7.9-6.91, 162−18.2−57.0-20.67, 486−24.8−43.3-6.31, 90−44.8−53.7-−35.8
1-h postload insulin (pmol/l)13, 1,050−40.8−60.6-−21.02, 398−16.6−39.2-6.07, 483−133.2−184.5-−81.8NDNDND
Total cholesterol (mmol/l)23, 2,1330.00−0.10-0.09NDNDND7, 499−0.09−0.23-0.051, 880.08−0.29-0.45
HDL cholesterol (mmol/l)14, 9240.00−0.04-0.04NDNDND7, 4850.02−0.02-0.061, 86−0.01−0.26- 0.24
LDL cholesterol (mmol/l)4, 402−0.08−0.41-0.25NDNDND4, 3120.10−0.07-0.27NDNDND
Triglycerides (mmol/l)21, 1,969−0.09−0.18-0.00NDNDND8, 5910.01−0.18-0.201, 89−0.04−0.40-0.32
Body weight (kg)16, 1,451−0.13−0.46-0.201, 1620.27−0.50-1.045, 397−1.90−4.01-0.211, 900.46−0.48-1.40
BMI (kg/m2)14, 1,430−0.17−0.25-−0.08NDNDND4, 230−0.39−0.83-0.05NDNDND
Occurrence of any side effect23, 3,8193.372.60-4.367, 1,3044.011.69-9.527, 6073.952.00-7.802, 2321.290.69-2.41
  • Continuous data are expressed as weighted mean differences; occurrence of side effects is expressed as odds ratio. Results are calculated with a random-effects model.

  • *

    * Number of comparisons (comp), participants (part).

  • A negative value indicates an advantage for acarbose or miglitol. ND, no available data.